FDA Approved Epidiolex Cannabis Cannabidiol CBD For Epilepsy Seizures [lt8xOxNDIfC]

FDA Approved Epidiolex Cannabis Cannabidiol CBD For Epilepsy Seizures [lt8xOxNDIfC]

| 1h 28m 28s | Video has closed captioning.

FDA Approved Epidiolex Cannabis Cannabidiol CBD For Epilepsy Seizures U.S. Government finally admits cannabis really does have health benefits! On 19th April 2018, A Food and Drug Administration (FDA) advisory panel unanimously voted to recommend approval of the first CBD prescription drug. The drug, called Epidiolex, uses cannabidiol (CBD) as an active ingredient to treat two severe forms of epilepsy that typically affect kids. Epidiolex now stands to become the first marijuana-based medication approved in the U.S. Epidiolex is made from a compound in the cannabis plant called cannabidiol (CBD) and is different to THC, which gives marijuana its euphoric effect. Having an FDA Approved CBD product available will make it much easier for researchers to study it for other conditions. A recent study published in The New England Journal of Medicine suggested that CBD oil could decrease the number of convulsive seizures in epilepsy patients. A 2017 World Health Organization (WHO) report on cannabidiol included an overview of diseases for which CBD oil may have therapeutic benefits. The WHO report cited evidence that CBD oil may be a useful treatment for Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and more… Based on the Epidiolex clinical trial, research and scientific studies conducted prior to Epidiolex FDA approval, thus far, there have been no Epidiolex side effects that concerned the FDA enough to not approve Epidiolex CBD oil for epilepsy seizures. For those wishing to buy Epidolex online, we're not yet aware of the GW Pharmaceuticals Epidiolex cost or availability however would expect to start to filter through as we get closer to final FDA approval for Epidiolex. Brightfield Group, a market research firm based in Chicago, expects CBD products to grow from 5% of U.S. cannabis sales today to 12% by 2021, and this doesn’t include the pharmaceutical channel that would open up with the approval of Epidiolex. The firm tracks several different distribution channels and suggests that total CBD sales of $288 million in 2017 grew 65% and predicts the entire category to grow 76% in 2018 to $505 million. Visit CBD Insiders, and join our growing community sharing their knowledge of the latest CBD Health, CBD Research, CBD Science & CBD News as well as exclusive interviews and in-depth reporting on influential players in the CBD industry. Follow Us On Facebook: Audio Credits: BenSound.com